Esperion Therapeutics (ESPR) Interest Expenses (2012 - 2026)

Esperion Therapeutics' Interest Expenses history runs 15 years deep, the most recent figure standing at $19.8 million for Q1 2026.

• Quarterly Interest Expenses rose 1.89% year-over-year to $19.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85.0 million (up 16.57% YoY) and the FY2025 annual result came in at $417.1 million, up 0.96% from the prior year.
• Interest Expenses was $19.8 million for Q1 2026 at Esperion Therapeutics, down from $22.6 million in the prior quarter.
• Across five years, Interest Expenses topped out at $24.7 million in Q4 2024 and bottomed at $13.7 million in Q2 2024.
• A 5-year average of $16.9 million and a median of $15.0 million in 2023 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses surged 73.07% — and 2025, when it dropped 8.2%.
• Esperion Therapeutics' Interest Expenses stood at $14.3 million in 2022, then gained by 5.08% to $15.1 million in 2023, then jumped by 63.76% to $24.7 million in 2024, then decreased by 8.2% to $22.6 million in 2025, then dropped by 12.54% to $19.8 million in 2026.
• Business Quant data shows ESPR's Interest Expenses at $19.8 million in Q1 2026, $22.6 million in Q4 2025, and $22.1 million in Q3 2025.